CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
  • About
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Rosemary Harrison Joins TCR Therapeutics as Chief Business and Strategy Officer

Rosemary Harrison Joins TCR...

Clinical Research Technology Leader RealTime Secures Growth Investment from LLR Partners

Clinical Research Technology Leader...

Catalyst Biosciences Announces Major Leadership Changes

Catalyst Biosciences Announces Major...

Merakris Therapeutics Partners with Miracles In Sight Eye Bank

Merakris Therapeutics Partners with...

BetterLife- Carleton University Research Team Secures Funding form Mitacs

BetterLife- Carleton University...

ClearPoint Neuro Appoints Lynnette C. Fallon to Board of Directors

ClearPoint Neuro Appoints Lynnette C....

Marc Drimer, CPA, Joins the Board of Directors of Curative Biotechnology

Marc Drimer, CPA, Joins the Board of...

James Pekarsky Joins Gelteq as Chief Financial Officer

James Pekarsky Joins Gelteq as Chief...

Rosemary Harrison Joins TCR Therapeutics as Chief Business and Strategy Officer

Rosemary Harrison Joins TCR...

Clinical Research Technology Leader RealTime Secures Growth Investment from LLR Partners

Clinical Research Technology Leader...

Catalyst Biosciences Announces Major Leadership Changes

Catalyst Biosciences Announces Major...

Merakris Therapeutics Partners with Miracles In Sight Eye Bank

Merakris Therapeutics Partners with...

BetterLife- Carleton University Research Team Secures Funding form Mitacs

BetterLife- Carleton University...

ClearPoint Neuro Appoints Lynnette C. Fallon to Board of Directors

ClearPoint Neuro Appoints Lynnette C....

Marc Drimer, CPA, Joins the Board of Directors of Curative Biotechnology

Marc Drimer, CPA, Joins the Board of...

James Pekarsky Joins Gelteq as Chief Financial Officer

James Pekarsky Joins Gelteq as Chief...

Clinical Potential of Combining AI and Decentralized Clinical Trials

Life Sciences Review | Saturday, December 19, 2020
Tweet

Leveraging AI and DCTs has become the core imperative to developing safe therapies as fast as possible.


FREMONT, CA: For years, enhancing clinical trial outcomes has focused on lowering time and cost. That focus, and the challenges of a pandemic, has triggered the digitization of the clinical trial life cycle. Decentralized Clinical Trials (DCTs), which put the patient at the heart of the trial experience and combine digital technologies, and artificial intelligence (AI), are joining forces to transform clinical research. Organizations are coupling DCT methodologies with AI in innovative means to reshape workflows across the clinical lifecycle, from trial design and patient recruitment to evidence generation. They are seeing dramatic decreases in time and cost of clinical studies. Read on to know more.


With the analytical tools and AI, the industry can benefit from this rich data to optimize patient recruitment, boost patient retention, reduce timelines, and maximize study results in future trials. AI can expedite target validation, trial design, and patient identification. DCTs can reduce the time and cost of clinical studies by widening patient access and retention due to enabling patients to participate safely and conveniently in their homes. 


DCTs also mitigate geographic, transportation, costs, and other hurdles that can enhance participants' diversity. The net impact is an enhancement in data quality as site-based transcription is avoided, plus an increase in efficiency for patients, sites, and study teams. Together, AI and DCTs can be a powerful tool.


To deploy AI with purpose, AI engines need more than just mountains of data. To offer accuracy, the data requires to be closely representative of the target population. As has been highly publicized in recent months, conventional clinical trials are often comprised of participants from urban areas and are predominantly white. DCTs drive AI engines since they inherently gather massive real-world, real-time data from diverse patient populations more inclusive of the world. By coupling both innovations, firms will enhance three crucial clinical trials, including trial design, patient recruitment, and evidence generation. AI’s continued maturation will widen its use across all stages of the patient journey and will lead to incredible breakthroughs in personalized medicine to rare diseases.


Check out: Top eClinical Trial Management Solution Companies


Weekly Brief

loading
> <
  • Regulatory Services 2022

    Top Vendors

    Current Issue
  • Clinical Stage Biopharmaceutical 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue
  • Regulatory Services 2022

    Top Vendors

    Current Issue
  • Clinical Stage Biopharmaceutical 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue

Read Also

Everything You Need to Know About Medical Lab Equipment and their Applications

Everything You Need to Know About Medical Lab Equipment and their Applications

Lung Cancer patients can see improved results with Immunotherapy along with Chemotherapy Before surgery.

Lung Cancer patients can see improved results with Immunotherapy along with Chemotherapy Before surgery.

Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks To Buy In 2022

Efficacy and Safety Data by Entasis Therapeutics from Landmark Phase 3 Attack Trial

Efficacy and Safety Data by Entasis Therapeutics from Landmark Phase 3 Attack Trial
How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

The several benefits Of Agricultural Genome Editing

The several benefits Of Agricultural Genome Editing

2027 Might See a Market Growth of Third-party Logistics at a CAGR of 7.1 percent

2027 Might See a Market Growth of Third-party Logistics at a CAGR of 7.1 percent

A Week To Celebrate The Significant Role Of Clinical Lab Professionals In Healthcare

A Week To Celebrate The Significant Role Of Clinical Lab Professionals In Healthcare
Loading...

Copyright © 2022 Life Science Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/clinical-potential-of-combining-ai-and-decentralized-clinical-trials--nwid-212.html